Intimation of Transcript of Q4 FY 26 for the Earnings Conference Call held on April 28, 2026.
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Rossari Biotech reported its highest-ever quarterly performance in Q4 FY26 with revenue of Rs. 684.9 crore (up 18% YoY) and EBITDA of Rs. 77.3 crore. Full year FY26 revenue was Rs. 2,396.4 crore (15% YoY growth) with EBITDA margins declining to 11.9% from 12.7% due to raw material price increases of 25-30% in March and adverse sales mix. All three segments delivered double-digit growth - HPPC (18%), Textiles (20%), and AHN (14%). The company sold non-core office space for Rs. 19 crore net income and plans to divest its loss-making B2C/institutional businesses (revenues ~Rs. 250-260 crore). CAPEX plans have been rephased from Rs. 192 crore to Rs. 50-75 crore for FY27, with a goal to become debt-free in 18 months. New pharma segment entry is planned, which management expects to have the highest gross margins.
The management guided for minimum 15% revenue growth and 12-13% EBITDA margins in FY27, with margin improvement expected from exiting loss-making B2C businesses, moving to higher-margin pharma/oil & gas segments, and operating leverage from new capacities. Declining raw material costs and successful price pass-through should support margins.